The European Neuromuscular Centre (ENMC) pathological classification criteria of idiopathic inflammatory myopathies (IIMs) are debatable. The aim of this study was to explore their practicability and reproducibility. We conducted a retrospective analysis of 57 cases of IIMs excluding dermatomyositis (DM) and sporadic inclusion body myositis (sIBM) by in-depth analysis of muscle biopsies and comparisons of the clinical characteristics among polymyositis (PM), non-specific myositis (NSM) and necrotizing autoimmune myopathy (NAM). In 57 non-DM/sIBM-IIM cases, 25 were classified as PM, 15 as NSM, and 17 as NAM. Among them, 51 underwent multilevel sectioning examination of biopsies, with pathological changes at different levels warranting diagnostic rectification in 11 patients (21.57%): 4 PM were reclassified as NSM, and 7 NSM as NAM. Applying atypical CD8þ T cells surrounding non-necrotic muscle fibers resulted in diagnostic rectification from NSM to PM in 2 patients; using 20 T cells (instead of 10) as the threshold for the perivascular infiltration led to diagnostic rectification from NSM to NAM in 9 patients. There were no differences in disease duration or treatment outcomes among the subgroups. The strict pathological criteria to distinguish non-DM/sIBM-IIMs are of limited practicability and reproducibility, and may be of limited clinical significance.
INTRODUCTION
Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria proposed by the European Neuromuscular Centre (ENMC) international workshop, IIMs are classified into 5 categories: polymyositis (PM); non-specific myositis (NSM); dermatomyositis (DM); necrotizing autoimmune myopathy (NAM); and sporadic inclusion body myositis (sIBM) (1) (2) (3) . These classification criteria defined 3 subgroups of non-DM/sIBMIIMs: PM, NSM, and NAM, which were mostly categorized as PM according to the previous diagnostic criteria ( [4] [5] [6] .
The ENMC classification criteria were developed in order to establish a guideline for standardized diagnostic workup and, subsequently, to explore the possibilities of international randomized controlled trials. However, these criteria have been only occasionally applied (7) (8) (9) (10) (11) (12) (13) (14) . Moreover, several clinical studies adopting the ENMC classification criteria showed considerably varied prevalence of 3 non-DM/sIBM-IIM subgroups (15) (16) (17) (18) (19) (20) . In a series of 62 patients with myositis, PM was nonexistent (18) . There seems to have been considerable bias by using the ENMC pathological criteria for the diagnosis of PM, NSM, and NAM. In particular, sampling bias such as undersampling cannot be avoided since most pathological changes listed in the ENMC criteria are usually focal so that some subgroups of non-DM/sIBM-IIMs may be underdiagnosed and the others may be overdiagnosed (17, 21) . Furthermore, in the ENMC criteria, the measures of several pathological features (with the description of "surrounding", "scattered", "sparse", "slight," and "not evident") are not specifically defined, which may lead to marked inter-observer variability in the interpretation of muscle biopsies. All these factors affect the reproducibility of diagnosis of non-DM/ sIBM-IIMs when using the ENMC classification criteria.
Although multilevel serial sectioning examination can increase the sensitivity of the criteria and, more likely, make a specific diagnosis (15) , it deserves further investigation whether some non-DM/sIBM-IIMs can be reclassified into different subgroups after more sections and/or levels of muscle biopsy samples are examined. Moreover, with respect to clinical significance, there has been no comprehensive comparison of clinical characteristics and treatment outcomes among these non-DM/sIBM-IIMs under the ENMC classification.
The present study aimed to explore the practicability of the current ENMC classification criteria and reproducibility of non-DM/sIBM-IIMs by using these criteria. We reported the pathological findings of multilevel serial sectioning examination of muscle biopsies, with subsequent comparisons of the clinical, serological, histopathological characteristics and treatment outcomes among these 3 non-DM/sIBM-IIM subgroups.
MATERIALS AND METHODS

Participants
The study included 117 consecutive cases of patients with IIMs diagnosed by muscle biopsy and clinical findings between April 2005 and December 2016 at Qilu Hospital, China. Clinical data and serum samples were collected from these patients with IIMs. The inclusion criteria for participants were as follows: (i) less than 2 years of disease duration preceding the first visit to our hospital; (ii) fulfilling the clinical criteria proposed by the ENMC workshops for IIMs with an exception of sIBM; (iii) elevated serum creatine kinase (CK) level (not necessary in DM patients); (iv) at least 1 of 3 other laboratory changes listed in the ENMC criteria (not necessary in DM patients); and (v) meeting the muscle biopsy inclusion criteria and none of the exclusion criteria of ENMC workshop (1). Of particular note was 1 male participant who presented with a 2.5-month history of muscle weakness and an elevated CK level of 7708 U/L at the initial visit. Despite the absence of necrotic fibers and inflammatory cell infiltration in his muscle biopsy and myositis-specific antibody (MSA) in his serum, he responded well to steroid treatment. In this study, we categorized anti-synthetase syndrome as a non-DM/sIBM-IIM, which is compatible with the ENMC classification since anti-synthetase syndrome was not separated from non-DM/ sIBM-IIMs as a distinct entity. Of these 117 patients, 57 were diagnosed as non-DM/sIBM-IIMs without further subclassification. We reviewed their clinical manifestations, treatment and outcomes. This study was approved by the Qilu hospital (Qingdao) institutional ethics committee. Informed consent was obtained from all the patients and control individuals.
Clinical Assessment "Chronic progression" was defined as the duration from the disease onset to the first examination !12 months (22) . Muscle strength was evaluated by the ordinal 6-point 0-5 of manual muscle testing and severe weakness was defined as grade 3 in the weakest muscle (23) .
Treatment Outcome Measures
According to the definition of improvement by International Myositis Assessment and Clinical Studies Group (IMACS), improvement was defined as 3 of any 6 core set measures improved !20%, with no more than 2 worse by !25% (which cannot be manual muscle testing) (24) . Treatment outcomes were graded as follows: no improvement; mild improvement; moderate improvement; marked improvement; and return to baseline (25) . Favorable outcome was defined as marked improvement or return to baseline (25) .
Detection of MSA and Myositis-Associated Autoantibody
Patients' serum was stored at À80 C. MSAs including anti-signal recognition particle (SRP), anti-EJ, anti-Jo-1, anti-OJ, anti-PL-12, anti-PL-7, anti-Mi-2, anti-melanoma differentiation-associated gene 5 (MDA5), anti-transcriptional intermediary factor 1c (TIF1c), anti-nuclear matrix protein 2 (NXP2), anti-small ubiquitin-like modifier activating enzyme (SAE) as well as myositis-associated autoantibodies including anti-Ku, anti-PM-Scl 100, anti-PM-Scl 75, and anti-Ro-52 were detected by Euroimmun immunoblots in 57 patients with non-DM/sIBM-IIMs. Anti-3-hydroxy-3-methylglutarylCoA reductase (HMGCR) autoantibodies were tested by enzyme-linked immunosorbent assay in 57 non-DM/sIBM-IIM patients and 24 healthy controls.
Muscle Biopsies
Muscle biopsies were all performed at the initial diagnosis before corticosteroid treatment. In 57 patients with non-DM/sIBM-IIMs, serial frozen sections were re-stained with hematoxylin and eosin (H&E), anti-CD3 mouse monoclonal antibody (clone LN10; Zhongshan Golden Bridge Biotechnology, Beijing, China), anti-CD8 rabbit monoclonal antibody (clone SP16; Zhongshan Golden Bridge Biotechnology), antimajor histocompatibility complex class I (MHC-I) rabbit monoclonal antibody (clone EP1395Y; Abcam, Cambridge, UK), anti-major histocompatibility complex class II (MHC-II) mouse monoclonal antibody (clone CR3/43; Dako, Glostrup, Denmark), and anti-membrane attack complex (MAC) mouse monoclonal antibody (clone aE11; Dako) (Supplementary Data Fig. S1 ). Multilevel serial sectioning was made in 51 of 57 muscle samples from patients with non-DM/sIBM-IIMs who were selected after their initial pathological materials were reviewed and deemed sufficient for this multilevel sectioning examination. Specifically, the tissue blocks were serially sectioned at 6-lm thickness and examined according to the following protocol: 6 sections were cut and stained with H&E, anti-CD3, anti-CD8, anti-MHC-I, anti-MHC-II, and anti-MAC; the following 50 sections were cut and saved for other use; the next 3 consecutive sections were cut and stained again with H&E, anti-CD3, and anti-CD8; the following 50 sections were cut and saved; and the next 3 consecutive sections were cut and stained again with H&E, anti-CD3, and anti-CD8.
Because the ENMC criteria did not include a detailed, specific definition of some pathological features (e.g. "endomysial CD8þ T cells surrounding non-necrotic fibers" or "ubiquitous MHC-I expression" for the diagnosis of probable PM; or "scattered endomysial CD8þ T cells infiltrate" or "perivascular, perimysial inflammatory cell infiltrate" for NSM), based on our experience with some pilot studies, we specified the following pathological changes: (i) the presence of CD8þ T cells "surrounding" non-necrotic fibers was identified when CD8þ T cells occupying more than half of the non-necrotic fiber perimeter; (ii) "ubiquitous MHC-I expression" was noted when the immunoreactivity for MHC-I was seen in all non-necrotic muscle fibers; (iii) "perivascular, perimysial inflammatory cell infiltrate" was identified as more than 15 inflammatory cells identified in the perivascular, perimysial region; and (iv) "scattered endomysial CD8þ T cells infiltrate" was identified as more than 15 CD8þ T cells per high-power field (original magnification: 200Â) (Fig. 1) . If there is diagnostic rectification at the different levels, PM has a diagnostic priority over the other 2 forms, as does NSM over NAM. Subsequently, to explore the reproducibility of diagnosis of non-DM/sIBM-IIMs in different interpretation of pathological features, we defined "atypical surrounding" as the presence of more than 4 CD8þ T cells around a non-necrotic fiber but occupying less than half of the non-necrotic fiber perimeter, and "perimysial inflammatory cell infiltrate" as more than 10 or 20 inflammatory cells identified in the perivascular perimysial region, as mentioned in a previous study ( Fig. 1 ) (26) . In order to reduce inter-observer variability, all these biopsies were consistently reexamined by a neurologist with neuromuscular pathology training (Y. Hou, the first author) during the retrospective analysis. To avoid preoccupation with the prior diagnosis and classification, the examiner was blind to the initial biopsy interpretation and clinical information. The diagnoses with the ENMC classification in reexamination were compared with the primary diagnoses by another neurologist with neuromuscular pathology training (one of the coauthors, who examined and reported the muscle biopsies at the initial examination). In the cases in which diagnoses were reclassified in reexamination, a consensus on the reclassification was reached between the examiner and second neurologist. There was typically no need for an amendment to the primary diagnosis in those cases for mainly 2 reasons. First, the primary diagnoses in clinical pathology reports at the initial examination were mostly less specific (without further classification as PM, NSM, and NAM) in those patients with non-DM/sIBM-IIMs. Second, our present study was investigative in application of the ENMC pathological classification criteria.
Statistical Analysis
Categorical variables were analyzed by Chi-square tests. The Fisher exact test was used in cases of a predicted frequency <5 or the total number <40. Continuous variables of multiple independent samples with normal distribution were compared by ANOVA, while those of 2 independent samples with normal distribution were compared by Student-t tests. Ordinal data were compared by Mann-Whitney U-test for simple comparisons and by Kruskal-Wallis test for multiple comparisons. Values of p < 0.05 were considered significant for simple comparisons, and the significant p level was corrected by Bonferroni method for multiple comparisons. All calculations were performed using the SPSS 20.0 statistical analysis software.
RESULTS
Diagnosis and Classification Based on the ENMC Criteria
One hundred and seventeen cases of IIMs were classified into 60 DM, 25 PM, 15 NSM and 17 NAM. Specifically, in muscle biopsies, T cells invading and surrounding nonnecrotic muscle fibers were identified in only 3 cases, CD8þ T cells surrounding non-necrotic muscle fibers were found in 7 cases, and ubiquitous MHC-I expression was seen in 21 cases. Of 15 cases of NSM, scattered endomysial CD8 þT-cell infiltrates were observed in 4 cases, and perivascular, perimysial inflammatory cell infiltrates were identified in all 15 cases. Of 17 cases of NAM, anti-SRP antibodies were found in 13 patients, and anti-HMGCR antibodies were detected in 1 patient.
Classification and Diagnosis Rectification Based on Muscle Biopsy Examination of Additional Levels
By using serial sectioning examination of 3 levels with more than 300-lm intervals, the diagnosis of a non-DM/ sIBM-IIM subgroup was changed to that of another subgroup in 11 of 51 (21.57%) patients. Of these 11 patients, 1 could be diagnosed as PM or NSM depending on whether T cells invaded and surrounded non-necrotic fibers; 3 diagnosed as PM or NSM depending on whether or not CD8 þ T cells surrounded non-necrotic fibers; and 7 diagnosed as NSM or NAM depending on the number of T cells in the perivascular areas (Table 1) . Notably, all 4 PM cases without ubiquitous MHC-I expression could be reclassified as NSM based on multilevel serial sectioning examination of muscle biopsies.
Classification and Diagnosis Rectification Based on Different Definitions of Diagnostic Pathological Features in Terms of the Number of Lymphocytic Infiltrates
Because the ENMC criteria did not specifically define "CD8þ T-cells surrounding non-necrotic fibers", the diagnosis in 2 more patients could be changed from NSM to PM if the "atypical surrounding" was regarded as one of the pathological criteria for possible PM. Similarly, 8 cases of NAM could be reclassified into NSM if the number of 10 T cells, instead of 15, was used as the threshold for the perivascular infiltration. On the contrary, 1 case of NSM would be reclassified into NAM if the number of 20 T cells was employed as the threshold for the perivascular infiltration. 
Clinical and Pathological Comparisons Among 3 Non-DM/sIBM-IIM Subgroups
The clinical features of 57 non-DM/sIBM-IIM patients are summarized in Table 2 . The percentage of positive anti-SRP autoantibodies was higher in NAM patients than that in PM patients (p ¼ 0.010). The CK levels upon the first visit to our hospital was significantly higher in NAM compared with that in PM (p ¼ 0.007) or NSM (p ¼ 0.016). No significant differences were found in age of onset, disease duration or immunohistochemical staining patterns among 3 subgroups of non-DM/sIBM-IIM patients.
Long-term follow up (with a range of 12-140 months; the median of 38.85 months) was noted in 48 patients. One patient with anti-SRP who had a suspected cancer suffered a sudden death 35 months after the treatment. There were no differences in medication usage, mortality rates, and clinical courses including improvement, relapse and treatment outcomes among 3 subgroups of non-DM/sIBM-IIM patients (Table 3) .
Comparisons Between Anti-SRP, Anti-HMGCR, or Anti-aminoacyl Transfer RNA Synthetase Autoantibody-Positive and MSA-Negative Groups
The CK levels were higher in the anti-SRP-positive patients than those in MSA-negative patients (p ¼ 0.012), and harder to return to the normal value in anti-HMGCR-positive patients compared with MSA-negative patients (p ¼ 0.035). The duration from the disease onset to the first examination was shorter in anti-aminoacyl transfer RNA (ARS)-positive patients compared with MSA-negative patients (p ¼ 0.006). No significant differences were found in other clinical features or treatment outcomes among these 4 subgroups associated with autoantibodies (Tables 4 and 5 ). Furthermore, all 5 patients with anti-HMGCR were not exposed to statin. All 4 patients with 2 kinds of MSA (i.e. 2 patients with positive anti-ARS and anti-SRP and 2 patients with positive anti-Mi2 and anti-SRP) showed favorable treatment outcomes. Anti-MDA-5, anti-TIF-1c, anti-NXP-2 and anti-SAE were not found in these 57 patients.
DISCUSSION
To explore the practicability of the ENMC classification criteria for IIMs and reproducibility of non-DM/sIBM-IIMs by using these criteria, we performed multilevel serial sectioning examination of muscle biopsies and compared the clinical features and treatment outcomes among PM, NSM and NAM. To our knowledge, the present study is the first to conduct this kind of multilevel sectioning investigation with comprehensive comparisons among these 3 subgroups of non-DM/sIBMIIMs.
Our findings suggest that the practicability of the ENMC classification criteria is limited to some extent, given the following. First, the pathological changes listed in the ENMC criteria are greatly influenced by sampling methods used in the examination of muscle biopsies. A 6-lm-thick microscopic section (e.g. sampled from a 1.0-to 1.5-cm-long muscle biopsy) is extremely tiny, and thus, even under the guidance of high-sensitivity magnetic resonance imaging, some focal or patchy pathological features such as T cells surrounding and invading non-necrotic fibers and perivascular infiltration may be easily omitted (6, 21, 27) . Our study revealed that 11 tissue samples, accounting for more than 20% of the total specimens, were re-diagnosed as another subgroup of non-DM/sIBM-IIMs after further examination of 3 levels with more than 300-lm intervals. Second, different interpretations of some pathological features listed in the ENMC classification criteria affect the reproducibility of diagnosis of these non-DM/sIBM-IIMs. In particular, employing the number of 10 T cells instead of 20 as the threshold for the perivascular infiltration resulted in the reclassification of more than 50% of NAM to NSM, and using the number of more than 4 CD8þ T cells as "the atypical" surrounding non-necrotic muscle fibers led to an 8% increase in the proportion of PM. Furthermore, the variance could be even greater if lymphocytic infiltrates would be evaluated only by routine histological methods without immunohistochemical stains.
The aforementioned findings may also explain why there is a marked variation in the proportions of 3 non-DM/ sIBM subgroups meeting the ENMC classification criteria in previously published studies that demonstrated the percentages of PM ranging from 0% to 67%, NSM from 5% to 89%, and NAM from 4% to 56% of all non-DM/sIBM patients all over the world (15, 16, (18) (19) (20) 28) . Even in the same country, the percentages of each subgroup vary significantly in different studies. For example, a Japanese study showed that the percentages of PM, NSM, and NAM were 10%, 74%, and 16%, respectively, compared to 9%, 38%, and 53%, respectively, in another study (20, 28) . The percentages of PM, NSM, and NAM in our study are 44%, 26%, and 30%, respectively, which differ from 21%, 23%, and 56%, respectively, reported by another Chinese neuromuscular center that is geographically close to our center (19) . Moreover, one of the potential pitfalls of the ENMC criteria is that their description of some pathological changes cannot be interpreted consistently in the previous studies. Many studies diagnosed PM based on inflammatory cells surrounding or invading non-necrotic DM, dermatomyositis; sIBM, sporadic inclusion body myositis; IIM, idiopathic inflammatory myopathy; PM, polymositis; NSM, non-specific myositis; NAM, necrotizing autoimmune myopathy; ILD, interstitial lung disease; MSA, myositis-specific autoantibodies; Anti-SRP, anti-signal recognition particle; anti-HMGCR, anti-3-hydroxy-3-methylglutaryl coenzyme A reductase; MAC, membrane attack complex; MHC-II, major histocompatibility complex class II. *p < 0.017 between PM and NAM as well as between NSM and NAM. † p < 0.017 between PM and NAM. DM, dermatomyositis; sIBM, sporadic inclusion body myositis; IIM, idiopathic inflammatory myopathies; PM, polymositis; NSM, non-specific myositis; NAM, necrotizing autoimmune myopathy; CK, creatine kinase.
*The percentage is obtained by dividing the number of patients with prednisone usage at the time of relapse by the number of relapsed patients and multiplying the result by 100. †
The percentage is obtained by dividing the number of patients in this category by the number of alive patients and multiplying the result by 100. DM, dermatomyositis; sIBM, sporadic inclusion body myositis; IIM, idiopathic inflammatory myopathy; Anti-SRP, anti-signal recognition particle; anti-HMGCR, anti-3-hydroxy-3-methylglutaryl coenzyme A reductase; anti-ARS, anti-aminoacyl transfer RNA synthetase; MSA, myositis-specific autoantibodies; ILD, interstitial lung disease; MAC, membrane attack complex; MHC-II, major histocompatibility complex class II.
TABLE 4. Clinical Characteristics of 4 Subgroups Associated With Autoantibodies in 57 Non
*Two patients with both anti-ARS antibodies and anti-SRP antibodies. † p < 0.05 versus MSA negative group.
muscle fibers plus ubiquitous MHC-I expression, which led to the underdiagnosis and even absence of PM (17, 20, 22, 29) . In the same sense, NAM was diagnosed by some studies based on focal infiltration of T cells or diffuse MHC-I expression, which resulted in the overdiagnosis of NAM (19, 25, (30) (31) (32) . Furthermore, the classification criteria were not precisely specified in a number of studies with poor standardization of non-DM/sIBMs and considerable confusion to readers (16, 18, 28, 33) . The subgrouping of non-DM/sIBM-IIMs based on the pathological changes may not be clinically necessary given the highly similar clinical manifestations and treatment outcomes, which is reflected by our present findings that are partly in accord with the results of a previous study showing similar disease course and treatment outcomes in DM, NSM, and NAM (18) . All patients with these 3 non-DM/sIBM-IIM subgroups are steroid-responsive, and the inflammatory cell infiltration pattern in non-DM/sIBM-IIMs cannot change their medication usage as well as disease prognosis. Among 3 non-DM/sIBM subgroups, the only significant difference is that NAM patients have a higher percentage of anti-SRP autoantibody positivity and a higher CK level.
There is continuing vigorous debate on the definition and prevalence of PM since the first case of PM was described by Wagner in 1863. The entity of polymyositis was established in 1958 when a remarkable monograph entitled "polymyositis" was published by Walton and Adams. This term was initially assigned to a group of acquired necrotizing myopathies with autoimmune pathogenesis that was evidenced previously by lymphocytic infiltration and steroid responsiveness; and recently by the presence of CD8þ T cells invading non-necrotic muscle fibers, diffuse MHC-I expression found in muscle biopsy, and MSA detected in blood serum. Many investigators have made great efforts to search for new measures that can reflect the autoimmune nature in muscle biopsy and/or serum for the diagnosis of PM. However, these measures are, unfortunately, not highly sensitive or specific, and thus the diagnosis of PM is still challenging. In 1980s, Arahata et al found CD8þ T cells invading non-necrotic muscle fibers on both light and immunoelectron microscopy in PM (34, 35) . This phenomenon was established as the canonical pathological criterion for the diagnosis of definite PM (6, 36) . However, it is rarely met in muscle biopsies even on multilevel sectioning examination, as described in the present study, which leads to the underdiagnosis of PM and great difficulty in determining the prevalence of PM. Our present study offers some insights into the debate on PM. First, the strict pathological criteria for PM (with the evolving concept) are not practical and less reliable because of the muscle sampling concerns. Second, the presence of CD8þ T cells invading non-necrotic muscle fibers, diffuse MHC-I expression in muscle biopsy, or autoimmune antibodies in serum may represent only a subset of PM, as this feature is not the sole indicator of the autoimmune process to support the diagnosis of PM. Third, to our viewpoint, it seems more practical that PM is still a syndrome in patients with necrotizing myopathy accompanied by any of definite (CD8þ T cells invading non-necrotic muscle fibers and positive MSA) or possible (diffuse MHC-I expression or focal lymphocytic infiltration) autoimmune changes in the muscle tissue or blood serum after ruling out known inherited myopathies and muscular dystrophies. In other words, even though nowadays we could classify PM and reclassify former "PM" cases more precisely by using pathological approaches, its classification would be less meaningful clinically because the sampling bias and marked inter-observer variability cannot be avoided. The clinical significance to distinguish PM from other non-DM/sIBM-IIMs may be limited, and the core nature of acquired necrotizing myopathy with the autoimmune pathogenesis is similar anyway in these non-DM/sIBM-IIM subgroups. Since the pathological criteria are insufficient for subgrouping non-DM/ sIBM-IIMs, as proposed recently in some published studies (37, 38) , an "integrated" IIM classification system based on a combination of clinico-sero-pathological features deserves to be explored. The optimal classification criteria should be based on more reliable and reproducible markers of pathological and serological autoimmune evidence. For example, we have found that patients with MSA showed characteristic clinical features. Specifically, the CK level was higher in the anti-SRP-positive patients and harder to return to the normal value in anti-HMGCR-positive patients than those of MSA-negative patients; the disease duration was shorter in anti-ARS-positive patients compared with MSA-negative patients, as previously reported (17) . Moreover, it has been noted that the laboratory detection of MSA is less influenced by the sampling and inter-observer bias. Therefore, we would propose that the MSA testing results can be used as one of the crucial criteria for the subgrouping of non-DM/sIBM-IIMs (20, 28, 33) . Considering the limitations of muscle biopsy and expectations of future MSA detection, the patients with subacute necrotizing myopathy may be regarded as potentially having PM after exclusion of hereditary muscle diseases. In patients with the working diagnosis of PM, steroid or immunosuppressant treatment should then be recommended also for diagnostic purposes. This therapeutic approach is well demonstrated by one of our patients (described in the Methods section). For the above reasons, there is an imminent need to develop new optimal diagnostic criteria, beyond the classification, for IIMs including all subgroups for diagnostic and therapeutic purposes, as well as research on the pathogenesis of IIMs. The major limitation of our study is the measurement of improvement in a retrospective design. Since the IMACS published consensus core set measures of IIMs with the definition of improvement in 2012 (24), we have used those measures, including a health assessment questionnaire and myositis disease activity assessment tool, in most patients retrospectively at the following visits rather than the initial visit.
In conclusion, the strict pathological criteria proposed by the ENMC workshops to distinguish the subgroups of non-DM/sIBM-IIMs are of limited practicability and reproducibility because of the muscle sampling bias and inter-observer variability. Given the highly similar clinical manifestations, the subgrouping of non-DM/sIBM-IIMs based on pathological changes in muscle biopsy samples may be of limited clinical significance. There is an imminent need to develop optimal diagnostic and classification criteria with more reliable and reproducible markers of pathological and/or serological evidence for IIMs including all subgroups. Because our study is based on a retrospective review of a relatively small number of patients in each group, future prospective studies in a large cohort of patients are necessary to support our conclusions.
